Differences in life expectancy of adrenocortical carcinoma patients vs. age‑ and sex-matched population controls.
Letizia Maria Ippolita JannelloAndrea BaudoLukas ScheipnerMario de AngelisCarolin SiechFrancesco Di BelloJordan A GoyalKira VitucciZhe TianStefano LuzzagoFrancesco A MistrettaMatteo FerroFred SaadFelix K H ChunAlberto BrigantiLuca CarmignaniNicola LongoOttavio de CobelliGennaro MusiPierre I KarakiewiczPublished in: International urology and nephrology (2024)
The most pronounced life expectancy detriment (84%) was recorded in metastatic ACC followed by locally advanced ACC patients (61%). Unfortunately, even in patients with localized ACC, life expectancy was 39% lower than that of the general population. Therefore, regardless of stage, ACC diagnosis results in a very pronounced detriment in life expectancy relative to the general population.